Takeda Pharmaceutical Company Limited (TSE: 4502) will present data on ADCETRIS® (brentuximab vedotin) in Hodgkin lymphoma at the 10th International Symposium on Hodgkin Lymphoma (ISHL), October 22 – 25, 2016 in Cologne, Germany. Four studies on brentuximab vedotin will be presented, including real-world evidence and Phase 4 data in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for stem cell transplantation or multiagent chemotherapy that will be announced for the first time.
“The data to be presented at this year’s ISHL are a proof point of the excellent progress we have made in furthering the clinical program of brentuximab vedotin,” said Dirk Huebner, M.D., Executive Medical Director, Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company. “Through our robust ongoing clinical investigation program, we have continued to see benefit of brentuximab vedotin, particularly in patients with Hodgkin lymphoma or other CD30-positive malignancies who would typically face a poor prognosis. We remain committed to bringing this important therapy to all patients who might benefit from it.”
Presentations will highlight scientific updates on brentuximab vedotin in patients with Hodgkin lymphoma, including the following abstracts accepted for poster presentations:
- Single-arm study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (RRHL) who are ineligible for stem cell transplantation (SCT) or multiagent chemotherapy.
- Real-World Effectiveness of Brentuximab Vedotin (BV) vs. Other Treatments in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL) Post Autologous Stem-Cell Transplantation (ASCT).
- Brentuximab vedotin (BV) in Patients who are Ineligible for Autologous Stem Cell Transplant (ASCT) with Relapsed or Refractory Hodgkin Lymphoma (rrHL): A UK and Germany Retrospective Study.
- Risk Factors (RFs) for Relapse in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL) after Autologous Stem Cell Transplant (ASCT): A Real-World Analysis in Germany and the United Kingdom (UK).
For more information, the ISHL program is available here: https://www.hodgkinsymposium.org/program/schedule. Takeda is the Jubilee sponsor of the 2016 congress.
About Hodgkin LymphomaLymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell expresses CD30.
ADCETRIS® (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing proprietary technology by Seattle Genetics. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells.
ADCETRIS was granted conditional marketing authorization by the European Commission in October 2012 for two indications: (1) for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following autologous stem cell transplant (ASCT), or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). In January 2016, the European Commission approved a Type II variation to include data on the retreatment of adult patients with Hodgkin lymphoma or sALCL who previously responded to ADCETRIS and who later relapse. In June 2016, the European Commission extended the current conditional approval of ADCETRIS and approved ADCETRIS for the treatment of adult patients with CD30-positive Hodgkin lymphoma at increased risk of relapse or progression following ASCT. ADCETRIS has received marketing authorization by regulatory authorities in 65 countries. See important safety information below.
ADCETRIS is being evaluated broadly in more than 45 ongoing clinical trials, including the Phase 3 ALCANZA trial in CD30-positive cutaneous T cell lymphoma (CTCL) and two additional Phase 3 studies, one in frontline classical Hodgkin lymphoma (ECHELON-1) and one in frontline CD30-positive mature T-cell lymphomas (ECHELON-2), as well as trials in many additional types of CD30-positive malignancies.
Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and Takeda are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.
Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.
|European MediaKate Burdkate.email@example.com|
+44 7974 151510
|Media outside Japan/EUSara Noonansara.firstname.lastname@example.org|
+81 (0) 3-3278-2417
Takeda (TSE: 4502) er et forskningsbasert, globalt selskap med hovedvekt på legemidler. Selskapet er til stede i mer enn 70 markeder og satser blant annet innen spesialområder som kreft, mage/tarm og vaksiner.
Som det største farmasøytiske selskapet i Japan, og et av de ledende globale selskapene i industrien, arbeider Takeda, gjennom medisinsk innovasjon, for bedre helse for pasienter over hele verden.
I Norge har Takeda cirka 280 medarbeidere og et eget produksjonsanlegg i Asker utenfor Oslo. Målt i volum er Takeda landets største leverandør av legemidler. Takeda har et bredt spekter av reseptbelagte medisiner til sykehus, spesialister og allmennpraktiserende leger. Takedas reseptfrie medisiner og kosttilskudd selges i apotek.
Takeda kjøpte i 2011 Nycomed, som har vært en ledende aktør i norsk legemiddelindustri og en viktig del av nordmenns hverdag i over 140 år. Selskapet har skapt, utviklet og produsert flere av landets mest kjente legemidler. Den arven skal Takeda bygge videre på og jobbe for bedre helse og et friskere Norge.
Mer informasjon om Takeda på www.takeda.com
Mer informasjon om Takeda Norge på www.takeda.no